Safety of Certolizumab Pegol in Plaque Psoriasis: Pooled 96-Week Data from Three Phase 3, Multicenter, Randomized, Placebo-Controlled Studies (CIMPASI-1, CIMPASI-2 and CIMPACT)

Main Article Content

A Blauvelt
B Strober
R Langley
S Kavanagh
C Arendt
M Boehnlein
M Lebwohl
K Reich

Keywords

psoriasis, certolizumab

Abstract

Abstract not available.

References

1. Kurd SK and Gelfand JM. JAAD. 2009;60:218–24

2. Rachakonda TD. et al. 2014;70:512–6

3. Certolizumab Pegol Prescribing Information. Available at:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125160s270lbl.pdf [Last accessed: May 2019]

4. Gottlieb AB. et al. JAAD. 2018;79:302–14.e6

5. Lebwohl M. et al. JAAD. 2018;79:266–76.e5.